AZD0780 + AZD4954 for Healthy Subjects

This trial explores the interaction between two experimental drugs, AZD0780 (laroprovstat) and AZD4954, in the body. Researchers test how each drug affects the other's absorption and processing when taken alone and together. Healthy men and women with a body mass index (BMI) between 18 and 35 and a minimum weight of 50 kg may qualify for this study. Participants must not have any health conditions, such as liver or kidney disease, that could affect drug processing. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot have taken any lipid-lowering therapy or laroprovstat in the 3 months before the screening.

Earlier studies tested AZD4954 to assess its safety and tolerability. These studies examined the drug's mechanism in the body and its effects. Results indicated that AZD4954 was generally well-tolerated, with mild to moderate side effects. Common side effects included headaches and dizziness, but these were not severe.

AZD0780 is currently undergoing a Phase 1 trial, where researchers primarily assess its safety. This phase marks the first testing of a new treatment in humans, so data may be limited. However, if AZD0780 had shown serious safety issues in earlier tests, it would not have progressed to this phase.

Researchers are excited about the treatments AZD0780 and AZD4954 because they offer a new approach to addressing health conditions. Unlike many existing treatments that focus on symptom management, AZD0780 and AZD4954 have the potential to work by directly targeting the underlying causes of diseases. AZD4954, when combined with laroprovstat, might represent a new mechanism of action, providing a more targeted therapy. This could mean more effective results with possibly fewer side effects, which is a significant improvement over current options.

Research has shown that AZD4954 may help lower cholesterol by affecting its production in the body. This could benefit individuals with high levels of Lipoprotein(a), which is linked to heart disease. Studies have found AZD4954 effective in healthy adults, particularly those with elevated Lipoprotein(a). In this trial, participants in Cohort 1 will receive AZD4954 alone, followed by a combination of laroprovstat (AZD0780) and AZD4954. Cohort 2 will receive laroprovstat alone, followed by the same combination. Researchers are studying laroprovstat to understand its interaction with AZD4954, although specific data on its effectiveness alone is not yet available. The combination of these treatments is being explored to understand their synergistic effects in the body.²³⁶⁷⁸